SCYXSCYNEXIS, Inc.

$38M

Q3 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$334,000-49.4% YoY

Gross Profit

$334,000100.0% margin

Operating Income

-$8M-2516.5% margin

Net Income

-$9M-2572.2% margin

EPS (Diluted)

$-0.17

QoQ Revenue Growth

-75.5%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$526,000

Balance Sheet

Total Assets

$51M

Total Liabilities

$15M

Stockholders' Equity

$36M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$334,000	$660,000	-49.4%
Gross Profit	$334,000	$660,000	-49.4%
Operating Income	-$8M	-$10M	+18.6%
Net Income	-$9M	-$3M	-205.9%

Revenue Segments

License and Service

$334,000100%

SCYX Q3 2025 Earnings — SCYNEXIS, Inc. Revenue & Financial Results | Market Cap Arena